Freightliner Boosts Booking Speed and Accuracy with Automation from Tideworks and Decisions
29.5.2025 15:00:00 CEST | Business Wire | Press Release
Tideworks Technology Inc. (Tideworks), a leading provider of full-service terminal operating system (TOS) solutions, announced today the successful deployment of an advanced integration with Freightliner Ltd. (Freightliner), the UK’s largest maritime intermodal logistics operator. The integration enhances planning by reducing manual processes and improving consistency, speed and accuracy across Freightliner’s UK terminals. These enhancements support scalable growth and better asset utilization.
The solution connects Freightliner’s existing use of Tideworks’ Intermodal Pro® (IPRO) intermodal rail TOS with Decisions, a third-party, low-code automation platform engineered for AI-enhanced decision making, to enable intelligent, rule-based automation of rail booking and planning across Freightliner’s network of UK terminals.
“This integration marks a great step forward in Freightliner’s digital evolution,” said Thomas Rucker, president of Tideworks Technology. “By streamlining complex rail bookings with intelligent automation, we’re helping Freightliner reduce planning time, improve data accuracy and increase terminal throughput. As a strategic technology partner, we’re focused on delivering scalable, future-ready solutions that empower our customers to operate more efficiently and make faster, data-driven decisions.”
The deployment also leverages Tideworks’ Business Rules Engine and enhanced Planning API to send planning data to Decisions. The integration then applies terminal-specific rule sets to automate booking assignments to virtual railcars, streamlining previous manual processes. It also enhances system communication and improves data accuracy across Freightliner’s network.
“Our team worked closely with Tideworks to roll out this integration across our network of UK terminals, and we’ve already seen improvements in planning speed and consistency,” said Chris Cavanagh, terminal systems manager at Freightliner Ltd. “We see Tideworks as a strategic partner in our modernization efforts and look forward to continued collaboration to adopt emerging technologies that improve planning workflows and operational performance.”
Freightliner has partnered with Tideworks since 2008. This new project with Decisions highlights the increasing demand for adaptable, integration-ready systems in rail logistics. The integration rolled out across Freightliner’s UK terminals in 2024. With cloud-capable infrastructure, evolving data tools and support for API-based integration, the implementation reflects Tideworks’ focus on building scalable digital foundations to support long-term operational goals.
About Tideworks Technology
Tideworks Technology, Inc. is a full-service provider of comprehensive terminal operating system solutions for growing marine and intermodal rail terminal operations worldwide. The company helps more than 120 facilities run their operations more efficiently and profitably. From optimized equipment utilization to faster turn times, Tideworks works at every step of terminal operations to maximize productivity and customer service. For more information about Tideworks Technology, a Carrix solution, visit www.tideworks.com.
About Freightliner Ltd.
Freightliner is the UK’s largest maritime intermodal logistics operator, providing container transportation from all major deep-sea ports to a national network of inland terminals. The company is also a leading heavy haul rail freight operator, offering efficient, sustainable logistics solutions across the UK rail network. Through the unique combination of our own rail, terminals and road assets, our intermodal logistics is the only true end-to-end logistics solution in the UK making us the one and only logistics provider you’ll ever need.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529885991/en/
Contacts
Media Contact
Media Contact for Tideworks Technology
Carley Gray, Communiqué PR
Phone: (206) 282-4923 ext. 114
Carley@communiquepr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom